Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The prevalence of hepatitis-B antigen (HB s AG) and its antibody (anti-HBs) among 49 London hemophiliacs was compared with that among women attending an antenatal clinic and healthy blood donors from London and from two parts of the tropics (Mauritius and Zambia). The prevalence of HBsAG and anti-HBs was low in antenatal patients, London blood donors and blood donors from Mauritius. However, a high proportion of hemophiliacs (59%) were anti-HBs positive, this being comparable with Zambian blood donors (53%), although anti-HBs titers in hemophiliacs were much higher (GMT 1:342) than in Zambian blood donors (GMT 1:36). In contrast, HBsAG was detected in 29 of 250 (12%) Zambian donors but in only 3 of 49 (6%) hemophiliacs. Clinically overt hepatitis occurred in only two hemophiliacs. However, the presence of HBsAG-specific IgM in 7 of 29 (24%) anti-HBs-positive hemophiliacs suggests that a proportion of these patients recently experienced subclinical infection by hepatitis-B virus, Anti-HBs-positive hemophiliacs received a significantly higher number of- cryoprecipitate units than did those without anti-HBs(P less than 0.01). Five of seven hemophiliacs with high titers of anti-HBs (greater than 1:4,096) showed a decline in titer after 1972 which may have been associated with the introduction of screening of cryoprecipitate for HBsAG.
 ...
PMID:The prevalence of hepatitis-B antigen (HB S Ag) and its antibody (Anti-HB S) among London hemophiliacs and blood donors from London and two tropical areas. 93 73

20 years after the introduction of the hepatitis-B vaccine the question still remains unsolved as to how the 2 to 5 per cent of the vaccinees who, after basic immunisation, respond with no anti-HBs levels (0-10 IU/l nonresponder, NR) or low levels (11-99 IU/l low-responder, LR) should be boostered to acquire sufficient and long-lasting protective anti-HBs levels. In a retrospective analysis of booster results we found in 75 NR and LR that the probability for long-lasting protection is very low for NR, but better for LR (60%). In a second part of this publication, the efficacy of intradermal and intramuscular hepatitis-B boosters was examined by retrospective analysis of booster results among 26 NR and LR. A slight advantage of the intradermal application was found concerning post-booster anti-HBs increase and the maximal HBs values reached. Long-lasting protective anti-HBs values could not be established for either way of application. Finally, a survey of the literature summing up true results of intradermal hepatitis-B basic immunisations with reduced doses (mostly 2 micrograms), shows that whereas the seroconversion rates achieved by this method are almost compatible with those after regular basic vaccination, the GMT values were far lower than those after regular basic vaccination. Prospective and randomised studies are needed to show which kind of booster is most efficient for nonresponders and low-responders.
 ...
PMID:[Non- and low-response after preventive hepatitis B vaccination]. 928 24

In order to verify the antibody levels against coxsackievirus B(CVB) in different adults, specific anti-CVB-IgM and anti-CVB-IgG have been detected in 46 viral myocarditis, 121 viral-hepatitis patients and 108 healthy donors by using immuno-enzyme histochemical method, and the antibody titres were also tested. The results showed that the positive rate of anti-CVB in viral myocarditis group, viral hepatitis group and donor group were 80.4% (37/46), 25.6% (31/121) and 40.7% (44/108), respectively. The GMT of anti-CVB-IgM and anti-CVB-IgG in viral myocarditis group, hepatitis group and donor group were 1:84.84, 1:9.07, 1:64.00 and 1:179.27, 1:9.59, 1:21.42, respectively. The positive rate and GMT of anti-CVB-IgM and anti-CVB-IgG in viral myocarditis group were significantly higher than those in the other two groups. The positive rate had no statistical difference between men and women. The results indicate that the majority of the healthy population in Changsha area is susceptible for CVB and most cases of the viral myocarditis many be related to CVB infection. It is considered that CVB can cause many diseases. Furthermore, there are no effective vaccine against CVB so far. One should think of the probability of CVB infection when encountering a patient.
 ...
PMID:[Study of levels of antibody against coxsackievirus B in different adults in Changsha area]. 1193 68

A long-term immunogenicity study of a single dose live attenuated H2 strain hepatitis A vaccine is being conducted in healthy Indian children at KEM Hospital, Pune. 131 of the original 143 children vaccinated in 2004, were evaluated for anti-HAV antibodies 30 months post vaccination (2007). Seroprotective antibody levels >20 mIU/mL were demonstrated in 87.8 % subjects with an overall GMT of 92.02 mIU/mL. No hepatitis like illness was recorded in any of the subjects since vaccination.
 ...
PMID:Immunogenicity of single dose live attenuated hepatitis a vaccine. 2116 55